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Research
The current state and future needs for applica­
tion of toxicogenomic (TGx) technologies, 
including micro  array analysis, to risk assess­
ment was summarized recently in a National 
Academy of Sciences (NAS) publication 
[National Research Council (NRC) 2007]. 
The report points to the strong potential of 
the technology but acknowledges that neither 
the full impact nor broad implementation in 
the field of toxicology have been achieved. 
The NAS report identifies some of the practi­
cal challenges associated with array implemen­
tation, (e.g., cost, data storage requirements). 
The impact of genomics is palpable, especially 
in fields of gene and biomarker discovery, 
with succinct gene sets being correlated with 
human disease as well as response to treat­
ment or stratification (Chanrion et al. 2007; 
Dressman et al. 2007; Rimkus et al. 2008). 
However, the impact to other specialized areas 
of science including toxicology is still being 
assessed (Foster et al. 2007; Gant 2007).
In this article we summarize a survey that 
gathered insights into the value and impact of 
TGx micro  array gene­expression responses to 
evaluate chemicals and drugs in experimen­
tal and preclinical models. This survey, based 
on feedback from various user groups, offers 
unique insights complementary to the NAS 
report (NRC 2007). The survey was designed, 
written, and distributed by the Health and 
Environmental Sciences Institute (HESI) 
Committee on the Application of Genomics 
to Mechanism­based Risk Assessment. The 
goal of the survey was to obtain information 
on the current applications of TGx data and 
to identify the future challenges facing the 
field of TGx from different sectors (e.g., gov­
ernment, industry, academic) and job types 
(research vs. management) across the United 
States, Europe, and Japan. The survey was 
also designed to determine how various orga­
nizations are using micro  array technology 
to evaluate the safety of chemicals and drugs 
regarding public health and regulatory assess­
ment, the types of applications both in vivo 
and in vitro, the resources required, and the 
data­management challenges and solutions.
The HESI Genomics Committee is part 
of the nonprofit International Life Sciences 
Institute (ILSI) Health and Environmental 
Sciences Institute, a collaborative research 
organization that involves government, aca­
demic, and industrial scientists in the joint 
identification and resolution of toxicology 
and risk assessment issues.
The data generated by this survey provide a 
benchmark for the state of the science regard­
ing applications of TGx data and identify the 
challenges concerning the implementation 
and impact of TGx data from experimental 
and preclinical models for the purpose of con­
tributing to the safety evaluation of drugs and 
chemicals. The survey findings are intended to 
leverage experience about the value of TGx for 
chemical and drug evalua  tion regarding public 
health and to provide a frame of reference and 
resource to facilitate discussions within the 
scientific community and within organiza­
tions and by policy makers as the field of TGx   
continues to advance.
Methods 
Survey design and analysis. The survey questions 
and format were collaboratively designed, writ­
ten, and reviewed by multi  sector representatives 
from the HESI Genomics Committee. The final 
survey contained 62 multiple­choice questions 
focused on broad issue areas such as technologies 
employed, experimental approaches, organiza­
tional capacity and resource allocation, percep­
tions of benefits and hurdles, data storage and 
exchange, and future expectations. The survey 
was accessed and completed by respondents via 
the online survey hosting tool SurveyMonkey.
com (http://www.surveymonkey.com/). Results 
were compiled by SurveyMonkey.com and then 
downloaded to a structured query language 
database for analysis.
Survey distribution and response. An 
explanatory e­mail and link to the online sur­
vey was sent to approximately 300 potential 
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Ba c k g r o u n d: In spite of the application of toxicogenomic (TGx) data to the field of toxicology for 
the past 10 years, the broad implementation and full impact of TGx for chemical and drug evalua­
tion to improve decision making within organizations and by policy makers has not been achieved.
oBjectives: The goal of the Health and Environmental Sciences Institute (HESI) Committee on 
the Application of Genomics to Mechanism­based Risk Assessment was to construct and summarize 
a multi  sector survey, addressing key issues and perspectives on the current and future practical uses 
and challenges of implementing TGx data to facilitate discussions for decision making within orga­
nizations and by policy makers.
Me t h o d s : An online survey to probe the current status and future challenges facing the field of TGx 
for drug and chemical evaluation in experimental and nonclinical models was taken by scientists and 
scientific decision/policy makers actively engaged in the field of TGx within industrial, academic, 
and regulatory sectors of the United States, Europe, and Japan. For this survey, TGx refers specifi­
cally to the analysis of gene expression responses to evaluate xenobiotic exposure in experimental and 
preclinical models.
re s u l t s: The survey results are summarized from questions covering broad areas including technol­
ogy used, organizational capacity and resource allocation, experimental approaches, data storage and 
exchange, perceptions of benefits and hurdles, and future expectations.
co n c l u s i o n s: The survey findings provide valuable information on the current state of the science 
of TGx applications and identify key areas in which TGx will have an impact as well as the key 
hurdles in applying TGx data to address issues. The findings serve as a public resource to facilitate 
discussions on the focus of future TGx efforts to ensure that a maximal benefit can be obtained 
from toxicogenomic studies.
key w o r d s : applications, HESI survey, impact and hurdles, toxicogenomics. Environ Health 
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respondents. The distribution list included 
scientists in the government, academic, and 
industrial (chemical, consumer products, and 
pharmaceutical) sectors and was populated 
from existing HESI mailing lists and contacts 
related to the HESI Genomics Committee. 
Our focus was to obtain the opinion and per­
spective of scientists and decision makers who 
are either directly involved in the field of TGx 
or review TGx data. We believed that indi­
viduals familiar with the field could provide 
valuable input on the status of the field and the 
potential hurdles, challenges, and future direc­
tions. For questions where the total number 
of respondents from a given sector was < 5, 
the data were excluded from the discussion as 
providing insufficient information.
A total of 112 respondents completed the 
survey (~ 30% response rate). The geographical 
distribution of respondents by site was approx­
imately 64% from the United States, 25% 
from Europe, 6% from Japan, and the balance 
from other regions. Survey respondents were 
employed in a variety of sectors. The pharma­
ceutical industry (43%) accounted for almost 
half the respondents; government regulatory 
(26%) and research (11%) units accounted for 
another third; and academia (8%), biotechnol­
ogy (7%), and chemical (< 5%) accounted for 
< 20% of participants.
About 70% of the respondents had expe­
rience using micro  arrays or worked in an 
organization that used the technology. The 
remaining 30% were not direct practitioners 
but used micro  array data derived from exter­
nal genomics­based studies. Job functions var­
ied among respondents. Almost half described 
their job function as researchers or as manag­
ers in laboratory­based functions. Other job 
descriptions included executives, regulators, 
bioinformaticians, and some non  specified 
roles (Table 1). Most of the respondents were 
aware of the HESI Committee on Genomics 
(90%) and believe that TGx will have a posi­
tive impact in preclinical safety assessment of 
drugs and chemicals.
Results
The survey included a range of questions 
regarding toxicogenomic technologies used, 
organizational capacity and resource alloca­
tion within organizations, experimental 
application, data storage and exchange, and 
the impact and hurdles of TGx. The survey 
questions and results summary are avail­
able online (ILSI Health and Environmental 
Sciences Institute 2009).
Micro  array technology implementation. 
Technology resources. Survey respondents 
provided information on the types of genom­
ics array technology used during the past 
3 years (Table 2). Use was split evenly between 
one­channel oligonucleotide arrays and either 
two­channel or cDNA (complementary DNA) 
arrays with no particular sector­specific prefer­
ences observed.
Organizational capacity and resource 
allocation. The types of expertise retained in 
TGx groups varied, with no predominant 
must­have expertise. Approximately equal 
numbers of respondents across all sectors indi­
cated that their groups retained some expertise 
in micro  array and real­time polymerase chain 
reaction (PCR) technology, bio  informatics, 
and statistics, as well as biologic validation and 
follow­up activities. Expertise in regulatory 
framework applications was rarely reported 
as part of an internal TGx group, with the 
obvious exception of government regulators, 
who allocated up to 30% of internal staff for 
this activity.
Of the sectors surveyed, the pharmaceuti­
cal industry reported the highest total per­
centages of their full­time employees (FTEs) 
dedicated to laboratory work and data genera­
tion for TGx (~ 50% of staff dedicated to data 
generation). Government research and regula­
tory groups reported the lowest rates of in­
house TGx data generation by FTEs, as most 
of their activities are conducted via partner­
ships or contract research. About 15% of aca­
demic and pharmaceutical sector respondents 
also reported outsourced research.
Across sectors, design of TGx experiments 
was almost exclusively accomplished internally 
except in those cases where the respondent was 
responsible for managing a research program 
(presumably because external collaborations, 
grants, and so on were involved). Probe gener­
ation and hybridization was also generally con­
ducted internally, but external resources were 
required about 15–30% of the time across 
all sectors (academic, biotechnology, govern­
ment, and pharmaceuticals), suggesting that 
this is not a core activity in some laboratories. 
Sample preparation was conducted externally 
about 15% of the time, possibly when the 
experimental work was outsourced or part of a 
collaboration effort, as indicated by responses 
from the academic, government regulatory, 
and government research sectors.
Experimental applications of TGx. 
In vitro application of TGx. Survey respon­
dents indicated that in vitro applications 
account for approximately half of their TGx 
efforts. The in vitro studies were based on 
work in cell lines (86%) and primary cultures 
(84%), as opposed to organ cultures (30%). 
Human, rat, and mouse were the most fre­
quently used species and liver (82%) the most 
commonly used tissue. In vitro studies were 
used to identify mechanism of action (86%), 
compared with in vivo data (66%), as well as 
to identify potential biomarkers (61%) and 
compare animal and human tissue (52%).
In vivo applications of TGx. Respondents 
reported that their in vivo efforts generally 
focused on short­term studies (1–2 weeks) 
from rat, mouse, and dog, with the liver domi­
nating as the most routinely processed tissue, 
followed by kidney. The other tissues processed 
sometimes included intestine, heart, peripheral 
blood leukocytes, skeletal muscle, lung, uterus, 
and brain. Some respondents reported the 
processing of whole blood for identification 
or measurement of biomarkers of toxicological 
response. Histopathology and clinical chemis­
try measures were cited as necessary anchors 
to place genomic findings into the appropriate 
biological context. Additionally, TGx data 
were viewed as important to evaluate 68% 
of the respondents. Integration of TGx data 
with other preclinical data, a systems biology 
approach to analyzing and interpreting the 
data, is used by 38% of the respondents, and 
another 34% consider using it in the future.
Use of non–array­based gene expres­
sion analyses. Respondents were asked about 
the use of non–array­based approach (e.g., 
real­time PCR) to assess expression levels 
of specific genes. Non–array­based analyses 
were used primarily to confirm array results 
(60%) as well as to confirm the identifica­
tion of safety biomarkers (45%) and efficacy 
biomarkers (25%). Alternative measures of 
gene expression were also cited as a means to 
make repeated measures on a small number of 
transcripts (18%) and target charac  teriza  tion 
(23%). When asked how frequently confir­
matory analyses support the primary micro­
array findings, there was a difference in the 
expected percentage of confirmation reported 
by laboratory directors (50% confirmation 
rate) and bench scientists (30% confirmation 







Research program manager 8
Informatics/database manager 8
VP/executive decision maker 9
Regulatory development 15
Other 15
VP, vice president. 
Table 2. Type of high-density (> 6,000 data points) microarray technologies employed by respondents.
Respondents using technology (%)
Array type In 2005 In 2006 In 2007
One-channel oligo microarray 38.2 40.2 45.1
Two-channel oligo microarray 22.5 22.5 21.6
cDNA microarray 19.6 17.6 16.7
Other high-density transcriptomics 6.9 6.9 11.8Pettit et al.
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rate) compared with the responses from vice 
presidents (10% confirmation rate). These 
data suggest that the reliability of TGx tech­
nology is currently under  estimated or incor­
rectly communicated at higher levels within 
organizational structure. When micro  array 
results are followed by a second assay to detect 
gene expression, for example, real­time PCR, 
respondents from most sectors indicated that 
60–89% of the micro  array data are confirmed.
TGx data storage and analysis. Although 
one of the great strengths of genomic micro­
arrays is their ability to provide information 
about hundreds to thousands of gene sequences 
in a single assay, the storage and analysis of this 
information can pose significant challenges. 
This was highlighted in the survey by a series 
of questions relating to both the statistical 
approaches and database tools used to organize 
and interpret these large data sets.
Those using TGx technologies rely on 
a variety of resources to provide biological 
and mechanistic context to the gene changes 
observed via the micro  array experiment. For 
example, commercially and publicly avail­
able pathway annotation, Gene Ontology 
(http://www.geneontology.org/) annotation, 
and Entrez Gene (http://www.ncbi.nlm.nih.
gov/sites/entrez?db=gene) resources were used 
consistently across the sectors that were sur­
veyed. These resources allowed users to access 
commonly referenced descriptions of gene 
products and their associated biological, cellu­
lar, and molecular functions. Database usage 
for data analysis by respondents was fairly 
evenly split between the internally developed 
and maintained databases versus publicly 
available databases. Not surprisingly, a higher 
percentage of academic and government sci­
entists relied on public databases than did 
the private sector, which employed relatively 
more commercial in­house database prod­
ucts. When asked about the use of the public 
database resources, the same pattern followed; 
for example,   government/academic scientists 
generally cited them as very or somewhat use­
ful, in contrast to private sector respondents 
who were more equivocal in their praise for 
these resources.
Despite the complex bioinformatics exper­
tise required to manipulate and interpret these 
massive data sets, only about half the respon­
dents always or frequently consulted with a 
statistician when designing and analyzing a 
micro  array study. Principal component analy­
sis (PCA), hierarchical clustering, and analysis 
of variance/statistical analysis of micro  arrays 
(SAM) were the most commonly used statis­
tical methods for analyzing micro  array data 
across all the respondents.
Respondents considered data analysis and 
interpretation an important internal support­
ing expertise. The percentage of FTEs allo­
cated to this activity varied widely, possibly 
a reflection of the mix and complexities of 
ongoing activities within each group. In most 
sectors, < 30% of FTEs were allocated for data 
analysis and interpretation, although some 
respondents from the pharmaceutical sector 
(8%), government research sector (25%), and 
biotechnology sector (40%) reported that 
50–75% of available FTEs were allocated for 
analysis and interpretation.
Over the last several years, a number of 
standards for data formatting and data inclu­
sion for TGx/micro  array data have been devel­
oped. These include the MIAME (Minimum 
Information about a Micro  array Experiment) 
conventions for reporting micro  array data, the 
CEBS (Chemical Effects in Biological Systems) 
database standards, and the developing SEND 
(Standard for Exchange of Nonclinical Data) 
standards for reporting preclinical safety data. 
Almost half of the respondents comply with 
MIAME or MIAME­Tox standards in for­
matting their data per requirements put in 
place by many leading peer­reviewed journals. 
Significantly fewer (11%) cited the use of the 
SEND format.
Most of the respondents cited the value 
of sharing this type of data with collabora­
tors (83%), with regulatory agencies vol­
untarily (67%), and with public databases 
(61%). Respondents identified the following 
as the greatest benefits of TGx data sharing: 
identification and consensus­building around 
Figure 1. Major reasons cited as to the impact of TGx data from the sectors of biotechnology (Biotech), 
government research (Gov Res), pharmaceutical companies (Pharma), government regulatory agencies 
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novel biomarkers, standardization and har­
monization of approaches and interpretation, 
and providing a means to inform the regu­
latory community about the application of 
TGx data.
Impact of TGx. The greatest impact of TGx 
data viewed across sectors and job descriptions 
was the contribution to a) understanding bio­
logical mechanisms, b) identification of bio­
marker candidates, and c) identifying species 
differences.
These areas were regarded as the most 
rele  vant applications for TGx. The ability 
to influence lead compound selection was 
viewed as moderate to high impact, whereas 
identifying drug target and off­target effects 
were viewed as having a moderate impact. 
The use of TGx as a supplemental or sup­
portive data source for decision making was 
cited by about half of the respondents as hav­
ing a moderate impact. Respondents from 
academia regarded this to be a high­impact 
area for TGx, whereas the pharmaceutical sec­
tor responded that the impact would be low. 
The government regulatory respondents were 
more positive that TGx data could be sup­
portive (31% high, 38% moderate, and 31% 
low). The contribution of TGx to intellectual 
property was regarded as having a moderate 
impact (Figure 1).
Hurdles of TGx. As a reflection of the 
diversity of groups that conduct TGx studies, 
there appears to be no single driving factor that 
currently limits application of TGx technology 
(Figure 2).
Even though TGx is contributing to 
understanding biological mechanisms, it is still 
the opinion of virtually all sectors that the cur­
rent limited biological understanding of TGx 
data remains as a high hurdle to increasing 
the impact (≥ 50% respondents for each sec­
tor) of TGx data. Interpretation of TGx data 
by regulatory agencies was considered to be a 
hurdle of high concern by government regula­
tory respondents (54%) and academia (60%). 
Most job sectors viewed this hurdle as a mod­
erate to high concern. A conservative nature 
of organizations was also seen as a moderate 
to high concern by most sectors. If under­
standing of biological context is important 
for mechanisms, the survey may indicate that 
additional information remains to be gained 
for TGx data to have a greater impact.
Additionally, across sectors, about 20% of 
respondents continue to identify insufficient 
maturation of the technology and concerns 
about a lack of return on investment as limi­
tations. Other hurdles considered moderate 
included time to analyze and interpret data; 
inability to prospectively validate safety mark­
ers; specialized applications, such as identifying 
idio  syncratic drug reactions; lack of acceptance 
of approach by senior management within 
companies; and concerns of litigation from 
retrospective analysis.
Challenges associated with the exchange 
and formatting of data were cited as being 
of higher concern by public sector regulatory 
respondents than by other respondents. This 
response is consistent with publicly available 
guidance documents and presentations [Food 
and Drug Administration (FDA) 2007], indi­
cating that many regulatory agencies are still 
developing policies and database/data storage 
resources to address the receipt and storage of 
large data sets from a variety of sources. 
Those sectors less heavily invested in the 
use of TGx for basic research also cited lack of 
staffing and analytical capabilities as an imped­
iment to broader implementation. In the aca­
demic and government sectors, insufficient 
budgets for equipment, supplies/reagents, and 
outsourcing are perceived as limiting factors by 
up to approximately 25% of responses.
figure 2. Major reasons identified as to the hurdles of implementing TGx data from the sectors of biotechnology (Biotech), government research (Gov Res), 
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TGx in safety and risk assessment. Role 
in regulatory submissions. Ultimately, one of 
the most important benchmarks regarding the 
impact of TGx technology in safety assessment 
will be the inclusion of the data in regulatory 
submissions. Respondents were asked to answer 
questions regarding the current and future 
impact of TGx data on   regulatory   submissions.
At present, there are no requirements for 
submission of preclinical TGx data to major 
regulatory agencies in the United States, 
Europe, or Japan. However, most of these 
agencies have produced draft guidance docu­
ments and are encouraging submission on a 
voluntary basis:
•	Guidance for Industry: Pharmacogenomic Data 
Submissions (FDA 2007)
•	Genomic Data Submission (FDA 2009)
•	External Review Draft of the Interim Guidance 
for Micro  array‑Based Assays: Data Submission, 
Quality, Analysis, Management and Training 
Considerations (U.S. Environmental 
Protection Agency 2009)
•	Scientific Guidelines for Human Medicinal 
Products (European Medicines Agency 2009).
Respondents from regulated industries 
(17%) had submitted voluntary data, but 
nearly 50% suggested they would consider 
submission in the future. About 20% of 
pharma  ceutical respondent organizations had 
participated in a submission, but > 50% of 
the executive respondents from this sector felt 
the practice will increase in the future.
However, most of the respondents from 
the government regulatory sector felt that 
submissions would be useful and would 
significantly improve the safety assessment 
process by helping to explain mechanisms 
of toxicity. About half of all the regulators 
also expressed some concern about the lack of 
resources/approaches for analyzing these data 
within their agencies. Most of the respon­
dents from government regulatory (85%) and 
research (75%) sectors also felt that it would 
be beneficial to have a requirement to sub­
mit micro  array data, whereas pharmaceutical 
(53%) and academic (50%) respondents were 
less convinced. Although more than half of 
the respondents felt that there was value in 
providing TGx data as part of voluntary sub­
missions to regulatory agencies, only about 
one­third cited value in sharing these data as 
part of a required regulatory submission.
In contrast to the apparent enthusiasm 
to share micro  array data, substantial barriers 
may prevent these data from being shared. 
Almost 80% of the respondents cited intel­
lectual property/patent concerns as a potential 
barrier to the sharing of TGx data, and nearly 
50% of respondents also cited concerns about 
variability in data formats, inter  platform dif­
ferences, concerns about potential for mis­
interpretation, lack of incentive to share data, 
and legal concerns.
The main benefits of submitting TGx 
data as part of a submission package cited by 
respondents included the following:
•	Supporting	the	molecular	basis	of	toxicity	in	
response to a drug, or to chemicals in food 
and in the environment (80%)
•	Aiding	in	the	acceptance	of	biomarkers	(50%)
•	Contributing	significantly	to	an	improved	




However, respondents also expressed con­
cerns that submission of TGx data as part of 
a submission package might not be beneficial. 
Their concerns included the following:
•	Some	of	the	regulatory	agencies	have	not	
defined methodology to analyze genomic 
data in the existing safety assessment para­
digm (45%).
•	Until	the	molecular	mechanisms	and	path­
ways of toxicity are better understood, 
genomic data will be of limited use in the 
safety assessment paradigm (43%).
•	Without	established	methods	and	a	better	
understanding of mechanism, regulatory 
agencies may interpret the micro  array TGx 
data differently and come to a different con­
clusion (43%).
When questioned about the role of TGx 
data in influencing regulatory decisions, most 
private sector respondents indicated that the 
anticipated impacts over the next 2–5 years 
would be moderate to low. Government regu­
lators responding to the survey predicted a 
moderate to high impact in this time frame 
(31% high, 38% moderate). It was not pos­
sible to discern from the survey responses if 
this moderate level of enthusiasm represented 
the current state that could improve in the 
future or a general moderation in the overall 
enthusiasm for the potential for TGx to alter 
the science of toxicology.
Future uses of TGx. There was broad con­
sensus across job sectors (industry, academia, 
and government) as well as scientific positions 
(research and applied scientists, management, 
and policy makers) that toxicogenomic data 
would have a moderate to high impact in a 
variety of areas of safety and risk assessment 
over the next 2–5 years. Among the areas 
for which consensus emerged regarding the 
potential impact by TGx in the near future are 
a) understanding the biologic mechanism of 
action of the toxic effect, and b) identification 
of candidate biomarkers of toxicity.
Additional areas in which the respon­
dents considered that TGx will contribute 
knowledge included influencing lead com­
pound selection with respect to compound 
safety potential, identifying species differ­
ences in toxicity, and identifying drug target 
and off­target effects. Respondents were less 
optimistic about TGx data influencing the 
decision­making process in safety assessment, 
influencing regulatory decisions, and contrib­
uting to intellectual property for products or 
for a class of products.
Discussion
There is little doubt that genomics­based tools 
and analytical techniques are beginning to pay 
dividends to scientists and organizations who 
dedicate time and resources to these tools. 
One metric is the number of publications 
that derive some or all of their content from 
genomics­based methods. The past 7–10 years 
have exhibited a sharp rise in the number of 
scholarly articles relying on data obtained 
using genomic techniques. Less obvious, 
perhaps, are the current hurdles facing the 
TGx field and clear direction of the field in 
the immediate future. The present survey of 
a broad user base of TGx technologies was 
intended to both assess the state of the sci­
ence today and identify real and potential 
barriers to progress. The data not only provide 
valuable information on the current state­of­
the­art but, more important, also serve as a 
starting point for focusing future efforts to 
ensure that maximal benefit can be obtained 
from TGx studies.
From a demographic perspective, the sur­
vey respondents represented a cross­section of 
industry, government, and academic research­
ers from a variety of roles. Geographically, 
respondents were primarily from Europe, 
Japan, and the United States, which is not 
surprising given that most of the academic 
and industrial genomics data are produced 
from these regions. About half of the respon­
dents identified themselves as in­laboratory 
scientists or as managers of a laboratory. 
Thus, survey data related to technical aspects 
of genomics should be accurately represented. 
Of particular interest is the responses of the 
executives who allocate resources versus the 
technical practitioners of the science with 
regard to TGx and how the science can be 
managed as the field advances.
One clear and important point that 
emerged from these survey data was that there 
is a disconnect on the perceived value of TGx 
data from the viewpoint of the scientists who 
generate the data and the people in organi­
zations who have to defend the dedication 
of resources to these expensive technologies. 
For example, executives felt that confirma­
tory assays rarely led to a true confirmation of 
an initial result from a genomics experiment, 
whereas scientists more often felt that a sec­
ondary assay did indeed provide confirmation. 
The important question is whether the source 
of this apparent contradiction is a true dis­
agreement between data sets or, perhaps more 
seriously, a failure to correctly communicate 
these data. One thing is certain: The future of 
genomics technology is absolutely dependent Toxicogenomics, state of science
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on both data quality and quality of interpreta­
tion. Thus, accuracy and perception of data are 
both key areas for focus in the coming years. It 
certainly bodes well for both accurate interpre­
tation and communication of genomics data 
that computational tools and techniques are 
becoming more mainstream and user friendly. 
However, the availability of qualified bioin­
formatics experts and individuals who can 
effectively integrate the genomic/computa­
tional output with toxicological interpretation 
is still a crucial need for the field—one that 
will probably lag behind the technology until 
training programs for bioinformatics toxicol­
ogy specialists reach critical mass.
Another surprising result from the sur­
vey was the report of use of samples derived 
from in vitro studies for genomics analysis. 
The use of cell lines (86%) equaled the use of 
primary cultures (84%), followed by the use of 
organ cultures (30%). These data are intrigu­
ing, given that in vitro models are often criti­
cized for lack of relevance to more complicated 
in vivo systems, especially in toxicology stud­
ies where risk assessments are often based on 
highly integrated models. There are a number 
of reasons why in vitro models may be favored 
for use in genomics studies. First, because of 
their inherent simplicity, data interpretation 
can be more straightforward. This assertion 
is true when the research questions focus on 
receptor or pathway activation or inhibition. 
The downstream mediators for most recep­
tor systems, either membrane­bound or solu­
ble, are fairly well understood. For example, 
the battery of genes involved in signaling in 
response to aryl hydrocarbon receptor activa­
tion are very well characterized in a number 
of cell lines (Rivera et al. 2007). This suggests 
that genomics can provide rapid insight into 
pathways potentially involved in mechanisms 
of action or toxicity or into discovery of new 
ligands or inhibitors. However, more complex 
questions such as those involving bio  activation 
or complex metabolic cascades are still prob­
ably best addressed in more completely inte­
grated physiological systems. Second, the cost 
of generating samples from in vitro systems 
is substantially less than the costs required to 
generate samples from in vivo systems, even 
when one considers the expense of the infra­
structure required to maintain in vivo systems. 
The cost factor is especially important, given 
the fairly high cost of micro  array platforms 
and the subsequent burden the resulting data 
place on experts in an organization in terms of 
time and electronic data management. Thus, 
running inexpensive experiments to gener­
ate samples for use on an expensive platform 
makes intuitive sense as long as the science 
is sound. Finally, in vitro systems offer the 
advantage of rapid screening using smaller 
amounts of material such as compounds for 
pharmaceutical screening. It may be possible 
to explore a wider chemical space in a shorter 
time using in vitro systems. Although precise 
reasons for leveraging use of in vitro models 
for generation of genomics data are perhaps 
elusive, the practical aspects cited above for use 
of in vitro systems undoubtedly play a role.
This survey also included a series of ques­
tions intended to characterize the challenges of 
genomic data management, use, and sharing. 
The survey demonstrated the perception that 
there is value in sharing genomics data both 
within an organization and between organiza­
tions. However, potential concerns did emerge 
with regard to data sharing. The primary issue 
cited in these concerns centered on intel­
lectual property (i.e., patent and freedom to 
operate issues). The relatively large contribu­
tion of survey responses from private indus­
try may have added some bias to the issue of 
proprietary concerns, but these concerns are 
nonetheless valid and important as the field 
of genomics continues to mature. It should 
be mentioned that academic institutions are 
also vested in intellectual property concerns, as 
most prominent universities have a very keen 
sense of value that can be derived from dis­
coveries made by their own scientists and have 
resources in place to protect those discoveries.
It was not surprising that there was little 
consensus on the use of data standards for 
reporting TGx data. Other than the generally 
accepted MIAME convention, there is little 
standardization for reporting orthogonal data 
relevant to interpretation of micro  array results 
(e.g., pathology results or biochemical assay 
data), nor are developing standards for report­
ing data from nonclinical safety studies widely 
accepted. The responses indicate that a lack of 
standardization will continue to represent a 
barrier to sharing micro  array data and to the 
develop  ment of public databases. Thus, the 
lack of consensus on the use of data standards 
may reflect a lack of focus and understanding 
of an important and potentially rate­limiting 
step for acceptance of TGx data.
The disparity in the views regarding the 
expected impact that TGx data will have on 
regulatory decisions (i.e., high to medium by 
academics and regulators versus low by the 
private sector) suggests that additional dialog 
among stakeholders is essential. For example, 
if there are areas of clear need that can be sup­
ported by TGx data in the context of regula­
tory submissions, they need to be defined and 
articulated. On the other hand, if the technol­
ogy is finding wider acceptance within the 
private sector in non  regulated areas, then there 
may be a mis  understanding with regard to the 
most likely uses of the technology. Regardless, 
understanding these differences in opinion 
will be critical to achieving good partnership 
between the public and private sectors in 
advancing the technology.
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